PL353406A1 - Formulations for parenteral use of estramustine phosphate and albumin - Google Patents

Formulations for parenteral use of estramustine phosphate and albumin

Info

Publication number
PL353406A1
PL353406A1 PL00353406A PL35340600A PL353406A1 PL 353406 A1 PL353406 A1 PL 353406A1 PL 00353406 A PL00353406 A PL 00353406A PL 35340600 A PL35340600 A PL 35340600A PL 353406 A1 PL353406 A1 PL 353406A1
Authority
PL
Poland
Prior art keywords
albumin
formulations
parenteral use
estramustine phosphate
estramustine
Prior art date
Application number
PL00353406A
Other languages
English (en)
Polish (pl)
Inventor
Lorena Muggetti
Paolo Colombo
Alessandro Martini
Giovanni Buzzi
Original Assignee
Pharmacia & Upjohn S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9918779.1A external-priority patent/GB9918779D0/en
Priority claimed from IT99MI001998 external-priority patent/IT1313629B1/it
Application filed by Pharmacia & Upjohn S.P.A. filed Critical Pharmacia & Upjohn S.P.A.
Publication of PL353406A1 publication Critical patent/PL353406A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/16Blood plasma; Blood serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38Albumins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL00353406A 1999-08-09 2000-08-03 Formulations for parenteral use of estramustine phosphate and albumin PL353406A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9918779.1A GB9918779D0 (en) 1999-08-09 1999-08-09 Formulations for parenteral use of estramustine phosphate and albumin
IT99MI001998 IT1313629B1 (it) 1999-09-27 1999-09-27 Formulazioni di estramustina fosfato ed albumina per uso parenterale

Publications (1)

Publication Number Publication Date
PL353406A1 true PL353406A1 (en) 2003-11-17

Family

ID=26315835

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00353406A PL353406A1 (en) 1999-08-09 2000-08-03 Formulations for parenteral use of estramustine phosphate and albumin

Country Status (17)

Country Link
EP (1) EP1206266A2 (ru)
JP (1) JP2003506408A (ru)
KR (1) KR20020019967A (ru)
CN (1) CN1511037A (ru)
AU (1) AU6280900A (ru)
BR (1) BR0013276A (ru)
CA (1) CA2380312A1 (ru)
CZ (1) CZ2002376A3 (ru)
EA (1) EA200200234A1 (ru)
HU (1) HUP0202645A3 (ru)
IL (1) IL147745A0 (ru)
MX (1) MXPA02001395A (ru)
NO (1) NO20020631D0 (ru)
NZ (1) NZ517632A (ru)
PL (1) PL353406A1 (ru)
SK (1) SK1782002A3 (ru)
WO (1) WO2001010446A2 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100426450B1 (ko) * 2002-03-16 2004-04-13 박래옥 구연산, 알부민 및 아연을 함유한 항암 조성물
CN104587479A (zh) * 2002-12-09 2015-05-06 阿布拉西斯生物科学有限责任公司 组合物和传递药剂的方法
ZA200409537B (en) 2003-01-31 2006-10-25 Yamanouchi Pharma Co Ltd Stable solid medicinal composition for oral administration
CN1771080B (zh) 2003-04-08 2010-12-15 诺沃挪第克公司 包括至少一个色谱处理步骤的生产治疗用多肽或其前体的方法
WO2004089985A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Stable pharmaceutical compositions
DE102006024528A1 (de) * 2006-05-23 2007-11-29 Albupharm Heidelberg Gmbh & Co. Kg Neue, an der Tumorphysiologie orientierte Formulierung eines Zytostatikums, insbesondere von cis-Platin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59108800A (ja) * 1982-12-13 1984-06-23 Japan Atom Energy Res Inst 誘導ミサイル作用および制癌剤の徐放性機能をもつ微粒子
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same

Also Published As

Publication number Publication date
WO2001010446A3 (en) 2001-05-25
NO20020631L (no) 2002-02-08
HUP0202645A2 (hu) 2002-12-28
CA2380312A1 (en) 2001-02-15
CN1511037A (zh) 2004-07-07
EP1206266A2 (en) 2002-05-22
BR0013276A (pt) 2004-08-03
NZ517632A (en) 2004-02-27
HUP0202645A3 (en) 2004-06-28
SK1782002A3 (en) 2002-05-09
CZ2002376A3 (cs) 2002-06-12
EA200200234A1 (ru) 2002-06-27
KR20020019967A (ko) 2002-03-13
NO20020631D0 (no) 2002-02-08
MXPA02001395A (es) 2002-08-12
WO2001010446A2 (en) 2001-02-15
AU6280900A (en) 2001-03-05
JP2003506408A (ja) 2003-02-18
IL147745A0 (en) 2002-08-14

Similar Documents

Publication Publication Date Title
HUP0202477A3 (en) Use of phthalazine derivatives
HUP0200898A3 (en) Derivatives of venlafaxine and methods of preparing and using the same
HUP0101237A3 (en) Sustained release preparations
IL137445A0 (en) Pharmaceutically active compounds and methods of use thereof
TW427126U (en) Connection structure for fixture and containing article
EP1115396A4 (en) PHARMACEUTICALLY ACTIVE COMPOUNDS, AND METHODS OF USE THEREOF
GB2367103B (en) Connector and method of use of the connector
HUP0202729A3 (en) Compositions for parenteral use of estramustine phosphate and amino acids
EP1194147A4 (en) DERIVATIVES OF ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE
IL147745A0 (en) Formulations for parenteral use of estramustine phosphate and albumin
GB9921958D0 (en) Formulations for parenteral use of estramustine phosphate and sulfoalkylether-cyclodextrins
PL352409A1 (en) Derivatives of 1-trifluorometyl-4-hydroxy-7-piperidinyl-aminomethylochromane
GB9918779D0 (en) Formulations for parenteral use of estramustine phosphate and albumin
HK1041227B (zh) 一種緩釋植入體及其製備方法
IL133612A0 (en) Formulations containing estramustine phosphate and albumin
PL350963A1 (en) Use of arylalkanoylpyridazines
PL342767A1 (en) Thiagabin preparations of prolonged release and reduced side-effects
HUP0201610A3 (en) Derivatives of 4'-demycarosyl-8a-aza-8a-homotylosin
GB9911546D0 (en) Release of poorly soluble agents
AU6230499A (en) Method for preparing 2-chloropropionaldehyde and use of the same
GB9921954D0 (en) Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
ITMI991998A0 (it) Formulazioni di estramustina fosfato ed albumina per uso parenterale
AU7609200A (en) Event based system for use within the creation and implementation of educationalsimulations
AU5098099A (en) Preparation and use of alpha-keto bisphosphonates
EP1041986A4 (en) PHARMACEUTICAL ACTIVE COMPOUND AND METHODS OF USE

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)